Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 13, 2019

View Archived Issues

Role of p300 in BRD4-NUT-driven NUT carcinomas and novel dual BET/p300 bromodomain inhibitors

MAb targeting TREM1+ myeloid cells boosts antitumor immunity and checkpoint inhibitor sensitivity

Prelude initiates phase I study of PRT-811 in advanced solid tumors, gliomas and myelofibrosis

Encouraging results seen in phase II studies of NanoPac paclitaxel

Corcept initiates phase II study of miricorilant for antipsychotic-induced weight gain

Small-molecule STING agonist promotes durable antitumor immunity causing complete tumor regression

Case study points to protective AD gene

RNA controls muscle stem cells

24-week data presented from HMM0301 phase III monotherapy study of dorzagliatin

FDA approves IND for WP-1066

FDA places on hold the phase I/II IGNITE DMD study of SGT-001

New data presented for ParvOryx in human ovarian cancer explants

DCC-3116 as a promising inhibitor of autophagy in preclinical models of RAS-mutant cancers

Preclinical and preliminary first-in-human data presented for STRO-002

Chugai Pharmaceuticals presents phase I data for EOS-789

SentiBio presents novel allogenic cell therapy, SENTI-101

KD-025 meets primary endpoint at interim analysis of pivotal ROCKstar study in chronic GvHD

Positive data presented from initial cohort of phase IIb study of ORMD-0801 in T2D

Virginia Tech Intellectual Properties describes mitochondrial uncouplers

Celgene patents compounds for diffuse large B-cell lymphoma

Macrocyclic oligopeptides identified at Roche

Vertex, Merck & Co. describe endoplasmic reticulum stress inducers

New P2X7 receptor antagonists identified at Shionogi

Break out the sparkling apple cider for DUR-928 alcoholic hepatitis data

New exploratory phase I/II study in Japan assesses NS-089 in Duchenne muscular dystrophy

Bellerophon reports initial data from acute hemodynamic study of INOpulse

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...